Preclinical Research
AOD9604’s lipolytic signal was worked out in mice, not in an approved obesity drug
Heffernan and Ng described a C-terminal fragment of growth hormone that increased fat metabolism in obese mice without the IGF-I rise of intact GH. It was not approved as a weight-loss medicine.
AOD9604 is a synthetic fragment corresponding to a lipolytic region of human growth hormone, roughly the C-terminal stretch around residues 177–191, modified for stability. Ng and colleagues reported metabolic studies of that fragment. Heffernan and colleagues then tested human growth hormone against the fragment in obese mice and in mice lacking the beta-3 adrenergic receptor. The fragment increased lipolysis. Unlike intact growth hormone in those experiments, it did not drive the same IGF-I response. The beta-3 receptor work was the proposed mechanism.
What mouse lipolysis does not become
A fragment that burns fat in an obese mouse is a lead, not a drug. AOD9604 was taken into human obesity research and did not emerge as an FDA-approved weight-loss medicine. That negative institutional fact matters as much as the positive mouse papers. Secondary sites often cite the mouse mechanism and omit the absence of an approval.
How to summarize it
Say that preclinical work supports a beta-3 adrenergic lipolytic action distinct from IGF-I elevation, and link both PMIDs. Do not translate the mouse milligram-per-kilogram plan into a human course. Do not treat a research vial as the material Ng or Heffernan injected. The papers are about a defined synthetic fragment in controlled animal studies.